To ask the Secretary of State for Health and Social Care, pursuant to the answer of 30 January 2023 to Question 129959 on Drugs: Prices, how many of the 24 commercial agreements that resulted in non-uniform pricing since 2020 were agreed through (a) The Cancer Drugs Fund, (b) routine commissioning and (c) the Innovative Medicines Fund.

Of the 24 commercial agreements that resulted in non-uniform pricing since 2020, 11 were agreed through the Cancer Drugs Fund and 13 were agreed through routine commissioning. NHS England and NHS Improvement (NHSE&I) and the National Institute for Health and Care Excellence (NICE) will lead a public engagement exercise on proposals for the Innovative Medicine Fund in due course. NHSE&I and NICE will continue to work collaboratively in line with NHSE&I’s published commercial framework to negotiate deals with industry that enable patients to access the most innovative and effective new medicines and ensure the National Health Service gets the best value.